Logan Lutton

World AIDS Day highlights ongoing challenges in HIV prevention and treatment, urging renewed commitment to end the epidemic and support affected communities.

A new report reveals the heavy personal and economic toll of MS and recommends more complete, patient focused approaches to measuring and managing the disease.

Telehealth mostly replaces in-person visits, with a 74% substitution rate, indicating lower federal costs and sustained value beyond the pandemic.

Nicotine dependency is a worldwide health threat, especially for HIV patients, who are more likely to smoke and to have health complications than healthy patients.

Here’s what you missed this week on Managed Healthcare Executive.

This year marks the fifth consecutive year Independence Blue Shield has received high marks for their Medicare plans.

The results of a new Kinsey Institute study show that masturbation eased menopause symptoms for a significant number of women, yet few clinicians discuss it, despite strong interest from patients.

The American Gastroenterological Association has released updated guidelines for treating moderate-to-severe Crohn’s disease, outlining 16 evidence-based recommendations that prioritize advanced therapies and reflect new medication approvals since 2021.

Health benefit costs for employees are projected to rise 6.7% in 2026—the largest increase in 15 years—as employers grapple with escalating prescription drug prices, growing GLP-1 coverage and a broader push to offer diverse, cost-saving health plan options amid mounting affordability concerns.

Medicaid expansion increased overall PrEP access in the U.S., but significant racial, gender and structural disparities persist, limiting equitable HIV prevention despite rising national uptake.

Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States under a restricted-distribution program because of the drug’s risk of progressive multifocal leukoencephalopathy.

Here’s what you missed this week on Managed Healthcare Executive.

The investigational lenacapavir-bictegravir tablet has the potential to reduce the pill burden of HIV treatment, according to a recent news release.

The FDA has approved Poherdy as the first interchangeable biosimilar to Perjeta, expanding treatment options for adults with HER2-positive breast cancer across both early-stage and metastatic settings.

In this interview, Lasara Firefox Allen, MSW, shares insights on gender-affirming menopause care, the unique needs of gender-diverse individuals and the importance of educating healthcare providers to offer inclusive support.

Results from two studies show that fenebrutinib significantly reduced relapses and slowed disease progression when compared with currently available treatments.

Veterans in the healthcare workforce are promoted more often and stay longer than non-veteran peers, highlighting their valuable leadership skills amid growing national healthcare staffing shortages.

After reviewing new data that proves hormone replacement therapy does not increase a woman’s risk of receiving a breast cancer diagnosis, the FDA has removed the black box label.

Here’s what you missed this week on Managed Healthcare Executive.

New interim safety and efficacy data for primary biliary cholangitis (PBC) treatment Livdelzi (seladelpar) demonstrates sustained itch relief and the potential to slow disease progression.

Nearly all women experience a decrease in libido as they go through perimenopause and menopause, but it remains unaddressed

Here’s what you missed this week on Managed Healthcare Executive.

Although people are living longer with HIV, patients must still grapple with survivors’ remorse and the challenges of growing older within an ageist society.

Early childhood stressors, like divorce, could increase the risk of developing psoriasis later in life, highlighting the importance of emotional well-being, according to the results of a recent Swedish study.

Cardiovascular, Renal and Metabolic Conditions Increasingly Prevalent, Expensive for Medicare Fee-For-Service Population

Although dry eye disease (DED) affects millions of Americans, there is a lack of effective treatment options and discontinuation rates are high, according to an abstract presented at AMCP Nexus 2025.

An abstract presented at AMCP Nexus 2025 showed that Medicaid drug spend in 10 states in FY 2023 was approximately equal to or less than the national drug spending rate of 14%.

An abstract presented at AMCP Nexus 2025 showed the overuse of opioids following successful cancer treatment is detrimental to patient health and expensive.

Self-injected Brekiya (dihydroergotamine mesylate) is now available by prescription for patients suffering from cluster headaches and migraines with aura.

Fifty-four percent of patients ages 12 to 18 with severe alopecia noticed hair regrowth when given 4-mg of Olumiant (oral baricitinib), according to results of a study presented this week at the 2025 Fall Clinical Dermatology conference.